Company

Bank

Analyst

Coverage

Opinion

Wk chg

12/7 cls

Anika Therapeutics Inc. (NASDAQ:ANIK)

Summer Street

Mark Landy

Price target

Buy

-18%

$9.67

Landy lowered his target to $14 from $21 after FDA upheld a 2010 non-approvable letter for Monovisc to treat osteoarthritis of the knee on an appeal from Anika. The company said it plans to request a meeting with the agency to determine next steps for the single injection device to deliver hyaluronic acid, which is approved in the EU and Canada. The DePuy Mitek Inc. subsidiary of Johnson & Johnson (NYSE:JNJ) has exclusive rights in the U.S. (see B15).

Myriad Genetics Inc. (NASDAQ:MYGN)

Goldman Sachs

Isaac Ro

Downgrade

Neutral (from buy)

-5%

$27.35